Disease Domain | Count |
---|---|
Neoplasms | 5 |
Immune System Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Biosimilar | 6 |
Monoclonal antibody | 6 |
Biological products | 4 |
Enzyme | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Oct 2021 |
Sponsor / Collaborator |
Start Date16 Nov 2018 |
Sponsor / Collaborator |
Start Date13 Nov 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Dornase alfa biosimilar(Eden Biologics, Inc.) ( DNase I ) | Cystic Fibrosis More | Phase 1 |
Denosumab biosimilar(Eden Biologics) ( RANKL ) | Osteoporosis More | Phase 1 |
EB1006 | Neoplasms More | Preclinical |
EB1007 | Neoplasms More | Preclinical |
Ipilimumab biosimilar(Eden Biologics) ( CTLA4 ) | Melanoma More | Preclinical |